GVR Report cover Women’s Health Market Size, Share & Trends Report

Women’s Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS), By Region, And Segment Forecasts, 2020 - 2027

  • Published Date: Feb, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-1-68038-634-9
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 130

Report Overview

The global women’s health market size was valued at around USD 32 billion in 2019 and is projected to increase at a CAGR of 4.9% over the forecast period. An increase in the population of women aged over 60, a rise in the adoption of unhealthy lifestyle habits, and the introduction of novel medicines for women are some of the factors that drive market growth. Furthermore, favorable policies initiated by the government to improve women’s health and raise awareness are likely to drive market growth during the forecast period. Women are at a higher risk of diseases such as osteoporosis, osteoarthritis, anemia, menstrual health-related disorders, depression, and obesity. Hence, increasing incidences of these conditions are likely to boost the market growth in the coming years.

According to the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million in 2050. Moreover, breast cancer, cardiovascular diseases, and mental diseases significantly contribute to the burden of non-communicable diseases. Women most likely start to undergo menopause after the age of 48 wherein they experience hormonal changes that affect the quality of life. About 73.0% of postmenopausal women experience hot flashes. The Society of Obstetricians and Gynecologists of Canada (SOGC) estimated that 80.0% of women suffer from at least one symptom of menopause such as mood swings, interrupted sleep, and irritability.

Global women’s health market

In addition, changes in dietary habits, stress, and consumption of alcohol are the key factors responsible for hormonal imbalance among women. This is likely to cause fertility issues in women. Ovulation problems, endometriosis, and polycystic ovarian syndrome (PCOS) are the major known factors for infertility. According to the CDC, about 10.0% of women (6.1 million) between the age of 15 and 44 in U.S. have trouble conceiving. Hence, these factors drive the need for treating these health conditions, subsequently driving the market for women’s health.

Governments and various private organizations focus on women's health across the globe. Coverage plans provided to women is one of the key factors expected to drive the market in developed countries. For instance, various coverage plans in U.S. provide preventive services for women without any copayment charges. This includes anemia screening on a routine basis, folic acid supplements for women who may become pregnant, hepatitis B screening, breast cancer screening, and contraception. Healthy People 2020 was established by the Department of Health and Human Services which has a 10-year agenda to improve the health of all Americans.

Application Insights

Based on the application, the women’s health market has been segmented into postmenopausal osteoporosis, menopause, endometriosis, contraceptives, hormonal infertility, and polycystic ovary syndrome (PCOS). The postmenopausal osteoporosis segment accounted for one of the largest shares of the market in 2019, due to the growing population of women aged 40 and above and the launch of various drugs to cure menopausal osteoporosis and improve health.

The hormonal infertility segment is expected to grow rapidly owing to high fertility-related conditions in developed countries. Moreover, the easy availability of several medicines to cure hormonal imbalance and market players’ investments in new product development would drive the segment growth over the forecast period. Hormonal imbalance such as the imbalance of prolactin, estrogen, and thyroid is increasing in women due to factors such as stress, further driving the demand for medication to improve health.

Regional Insights

North America dominated the global women’s health market in 2019. This is attributed to the existence of key market players, reimbursement policies, supportive government regulations, approval and commercialization of products, and growing awareness about the importance of maintaining good health. The market is also driven by the increasing number of FDA approvals of menopausal drugs, high healthcare expenditure, and a rise in preference for biologics among women. In October 2018, the U.S. FDA approved TherapeuticsMD’s Bijuva, a soft gel capsule containing estradiol and progesterone. The drug is approved as a single pill hormone therapy for menopausal hot flashes.

 Women’s Health Market

Asia Pacific is projected to grow at the fastest rate over the forecast period. This is attributed to the rising awareness about women’s wellbeing and health, growing prevalence of osteoarthritis, infertility, and other disorders due to stress, and various government programs for increasing health awareness.

Women’s Health Market Share Insights

Some of the key players operating in the market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer; Teva Pharmaceuticals; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb; and Ferring B.V. Collaborations for product development, expansion of product portfolios, and regional expansion in emerging markets are the key strategic undertakings of these companies to increase their market share.

Market players focus on gaining FDA approval for new indications to prevent loss in revenues post-patent expiry. For instance, Prolia is recommended for postmenopausal women who are susceptible to bone fractures due to osteoporosis. The indications differ according to the approvals across various geographies. In U.S. for instance, it is mainly used as a second or third line of treatment for women who have suffered at least one or multiple osteoporotic fractures. In Europe, it is prescribed for women with a high risk of osteoporotic fractures and as a treatment of osteoporosis.

In May 2019, Agile Therapeutics resubmitted its new drug application for Twirla in response to a Complete Response Letter from the FDA in December 2017, which identified deficiencies in quality control for the product’s manufacturing process.

Report Scope



Base year for estimation


Actual estimates/Historical data

2016 - 2018

Forecast period

2020 - 2027

Market representation

Revenue in USD Million and CAGR from 2020 to 2027

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, Japan, China, Brazil, Mexico, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analysts working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global women’s health market report on the basis of application and region:

  • Application Outlook (Revenue, USD Million, 2016 - 2027)

    • Postmenopausal Osteoporosis

    • Hormonal Infertility

    • Endometriosis

    • Contraceptives

    • Menopause

    • Polycystic Ovary Syndrome (PCOS)

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.